PF-Atlas › Clinical Trials › NCT05637216
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Losartan 25 milligram capsule · Phase 2
Registry ID
NCT05637216
Phase
Phase 2
Status
Recruiting
Drug / intervention
Losartan 25 milligram capsule
Sponsor
Shaw Cancer Center
Start
2023-08-17
About this trial
Losartan 25 milligram capsule is evaluated in NCT05637216, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Shaw Cancer Center. Current status: Recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05637216 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.